Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals (CRVS) is a clinical-stage biopharmaceutical company advancing novel immunotherapies targeting T cell modulation through ITK inhibition. This page provides investors and industry stakeholders with timely updates on CRVS’s clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases, earnings reports, and research updates in one centralized location. Track progress across the company’s pipeline, including soquelitinib for T cell lymphomas and autoimmune conditions, as well as collaborations shaping its therapeutic platform.
Key updates include clinical trial results, partnership announcements, and financial performance. Bookmark this page to stay informed about CRVS’s advancements in immuno-oncology and immune-mediated disease research. Visit regularly for authoritative insights into the company’s scientific and operational progress.
Corvus Pharmaceuticals (CRVS) reported promising results from its Phase 1b clinical trial of mupadolimab, a monoclonal antibody targeting CD73, in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The study demonstrated tumor regression in patients resistant to prior anti-PD-1 therapy. Corvus is expanding patient enrollment in the trial and expects to release additional data in early 2022. Mupadolimab's unique mechanism may enhance immune responses and potentially overcome resistance to existing therapies.
BURLINGAME, Calif., Nov. 10, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation at the Jefferies London Healthcare Conference from November 16-19, 2021. The company will engage in one-on-one meetings with investors. Additionally, a pre-recorded corporate overview presentation by CEO Richard A. Miller will be available on-demand starting at 3:00 am ET on November 18. Attendees can register for the webcast here, and the presentation will be accessible for 30 days post-event.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present data from its Phase 1/1b trial of mupadolimab at the 2021 SITC Annual Meeting, scheduled for November 10-14, 2021. The data presentation will focus on activating CD73 on B cells as a potential immunotherapy for HPV-positive head and neck cancers. A poster session will take place on November 12, 2021, and a conference call/webcast to discuss the findings is set for 9:00 am ET. Mupadolimab is a humanized monoclonal antibody designed to enhance immune response against cancers.
Corvus Pharmaceuticals (CRVS) provided a business update and reported third-quarter financial results for 2021. The company's cash and marketable securities increased to $76.3 million from $44.3 million at year-end 2020, largely due to stock offerings. Their lead drug, mupadolimab, is being tested in several trials for non-small cell lung cancer (NSCLC) and HPV+ head and neck cancers, with results expected in 2022. The company incurred a net loss of $10.7 million in Q3 2021, higher than the previous year’s $9.8 million loss, driven by increased clinical trial costs.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced the approval of its partner Angel Pharmaceuticals' IND application to initiate a Phase 1/1b clinical trial for CPI-818 in relapsed/refractory T-cell lymphomas in China. Corvus holds a 49.7% equity stake in Angel Pharma, responsible for all development costs. CPI-818 is the only clinical-stage ITK-inhibitor in China and has shown promising interim results in earlier trials. The initiative aligns with Corvus’ strategy to enhance global product development, addressing a significant healthcare need in China.
Angel Pharmaceuticals announced the approval of its IND application for CPI-818, a unique ITK inhibitor, by the Center for Drug Evaluation in China. This drug targets relapsed/refractory T-cell lymphomas and is the only ITK inhibitor in clinical development. CPI-818 has shown promising anti-tumor activity and is currently in a multi-center Phase 1b/2 trial in the U.S. and Asia. The collaboration with Corvus Pharmaceuticals provides Angel with the rights to develop and commercialize CPI-818 in China, presenting a crucial step in addressing the unmet need for effective treatments in this patient population.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced positive results from a COVID-19 randomized controlled study involving 40 patients treated with mupadolimab, showing improved primary and secondary endpoints compared to placebo. The Phase 3 trial, though discontinued voluntarily, indicated a potential dose-response effect, particularly at 2mg/kg, with no reported adverse events. The company is also conducting a Phase 1b/2 trial for mupadolimab in oncology, with data expected to be presented at the SITC meeting in November.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced participation in two investor conferences in September 2021. The first event, the H.C. Wainwright Annual Global Investment Conference, is set for September 13-15, where CEO Richard A. Miller will offer a pre-recorded presentation available starting September 13 at 7:00 am ET. The second event, the Cantor Virtual Global Healthcare Conference, runs from September 27-30, with Dr. Miller presenting on September 29 from 3:20-3:50 pm ET. Webcast replays will be accessible for 90 days post-event.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced that its partner, Angel Pharmaceuticals, received approval for a Phase 1/1b clinical trial of CPI-818 in China for T cell lymphomas. This milestone, expected to initiate by year-end 2021, underscores Corvus’ global growth strategy. CPI-818, an ITK inhibitor, shows potential in treating T cell malignancies, with interim trial results demonstrating significant tumor responses. Additionally, Angel Pharma launched new R&D centers in China and the U.S., enhancing its capabilities in drug development.
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) reported its Q2 2021 financial results, revealing cash reserves of $66.5 million, up from $44.3 million at year-end 2020. The company continues to develop mupadolimab for HPV+ head and neck cancer and other viral-related cancers, having begun a Phase 1b/2 trial. Corvus discontinued its Phase 3 COVID-19 trial, reducing expected 2021 operating cash use to $35-$37 million, down from $46-$48 million. R&D expenses rose to $9.1 million, resulting in a net loss of $11.8 million for the quarter.